Hervycta Plus Information
Hervycta Plus is an allopathic medicine The correct dosage of Hervycta Plus depends on the patient's age, gender, and medical history. This information has been provided in detail in the dosage section.
Hervycta Plus Benefits & Uses
Hervycta Plus is used to treat the following -
Main Benefits
Other Benefits
- Gastric Cancer
Hervycta Plus Dosage & How to Take
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult(Female) |
|
| Geriatric |
|
| Adult |
|
Hervycta Plus Related Warnings
-
Is the use of Hervycta Plus safe for pregnant women?
Hervycta Plus shows severe side effect on pregnant women. For this reason, pregnant women should only take it after taking medical advice.
Severe -
Is the use of Hervycta Plus safe during breastfeeding?
Taking Hervycta Plus may lead to serious side effects if you are breastfeeding. Hervycta Plus should not be taken by breastfeeding women unless prescribed by the doctor.
Severe -
What is the effect of Hervycta Plus on the Kidneys?
Hervycta Plus does not damage the kidneys.
Safe -
What is the effect of Hervycta Plus on the Liver?
Hervycta Plus does not damage the liver.
Safe -
What is the effect of Hervycta Plus on the Heart?
There may be an adverse effect on the heart after taking Hervycta Plus. If you observe any side effects on your body then stop taking this drug. Restart this medicine only if your doctor advises you to do so.
Moderate
Severe Interaction of Hervycta Plus with Other Drugs
Hervycta Plus should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Hervycta Plus Contraindications
If you are suffering from any of the following diseases, you should not take Hervycta Plus unless your doctor advises you to do so -
- Angioedema
- Asthma
- COPD (Chronic Obstructive Pulmonary Disease)
- Pneumonitis
- Heart Disease
- Gastritis
- Pneumonia
Frequently asked Questions about Hervycta Plus
-
Is this Hervycta Plus habit forming or addictive?
Forming a habit of Hervycta Plus has not been reported.
No -
Is it safe to drive or operate heavy machinery when consuming?
After taking Hervycta Plus, you should not drive or work on any heavy machine, as Hervycta Plus can make you drowsy.
Dangerous -
Is it safe?
Hervycta Plus should be used only after doctor's advice.
Safe, but take only on Doctor's advise -
Is it able to treat mental disorders?
There is no benefit of taking Hervycta Plus for mental disorders.
No
Hervycta Plus Interactions with Food and Alcohol
-
Interaction between Food and Hervycta Plus
Taking Hervycta Plus with food does not harm your health.
Safe -
Interaction between Alcohol and Hervycta Plus
Due to lack of research, there is no information about the side effects of taking Hervycta Plus with alcohol.
Unknown
See all substitutes for Hervycta Plus
- Herclon Injection - ₹46309
- Eleftha 440 Mg Injection - ₹18995
- Tarzed 440mg Injection - ₹61288
- Hermab 150mg Injection - ₹21440
- Hervycta 440mg Injection - ₹18900
- Hervycta Plus 150mg Injection - ₹22347
- Hervycta Plus 440mg Injection - ₹39496
- Vicentra 150mg Injection - ₹22800
- Vicentra 440mg Injection - ₹59970
- Hervycta 150mg Injection - ₹6500
- Trasmab 440mg Injection - ₹54650
- Trazumab 440mg Injection - ₹52866
- Priunta 440mg Injection - ₹54264
- Priunta 150mg Injection - ₹17990
- Ontramab 440mg Injection - ₹19800
- Ontramab 150mg Injection - ₹8900
- Neuzumab 440mg Injection - ₹19800
- Neuzumab 150mg Injection - ₹8900
- Herti 440mg Injection - ₹54266
- Hersima 440mg Injection - ₹54662
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Herceptin® (trastuzumab)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 114-116